Bicalutamide significantly improved OS in patient with locally advanced disease ( hazard ratios ( HR ) = @ ( @ % confidence interval ( CI ) : @-@ @ , p = @ ) , regardless of baseline prostate-specific antigen ( PSA ) , with a survival benefit which was apparent throughout the study period .